Project description:Estrogen Receptor alpha (ERα) is a key driver of most breast cancers, and it is the target of endocrine therapies used in the clinic to treat women with ERα positive (ER+) breast cancer. The two methods ChIP-seq (chromatin immunoprecipitation coupled with deep sequencing) and RIME (Rapid Immunoprecipitation of Endogenous Proteins) have greatly improved our understanding of ERα function during breast cancer progression and in response to anti-estrogens. A critical component of both ChIP-seq and RIME protocols is the antibody that is used to pull down the bait protein. To date, most of the ChIP-seq and RIME experiments for the study of ERα have been performed using the sc-543 antibody from Santa Cruz Biotechnology. However, this antibody has been discontinued, thereby severely impacting the study of ERα in normal physiology as well as diseases such as breast cancer and ovarian cancer. Here, we compare the sc-543 antibody with other commercially available antibodies, and we show that 06-935 (EMD Millipore) and ab3575 (Abcam) antibodies can successfully replace the sc-543 antibody for ChIP-seq and RIME experiments.

2019-03-21 | PXD012930 | Pride

Elucidation of FOXP1 target genes in DLBCL by ChIP-Seq

Project description:Elucidation of FOXP1 target genes in DLBCL by ChIP-Seq

| PRJEB9851 | ENA

Identification of TEAD4 target genes in Human trophoblast stem cells (HTS) by ChIP-seq analysis.

Project description:Identification of TEAD4 target genes in Human trophoblast stem cells (HTS) by ChIP-seq analysis.

| PRJNA604989 | ENA

ChIP-seq identified transcription factor UvCGBP1-mediated target genes of Ustilaginoidea virens

Project description:ChIP-seq identified transcription factor UvCGBP1-mediated target genes of Ustilaginoidea virens

| PRJNA594387 | ENA

Identification of Pol II(G) target genes in mouse liver [ChIP-seq]

Project description:Identification of Pol II(G) target genes in mouse liver [ChIP-seq]